CDNA
CDNA news
Latest 4 stories · newest Sep 25, 2026
CDNA
CareDx reports Q2 2026 revenue of $132M, raises full-year 2026 guidance to $490-500M
Second quarter 2026 revenue increased 52% year-over-year to $132 million. The company raised its 2026 revenue guidance to $490M-$500M and AEBITDA guidance to $66M-$78M. The growth was driven by strong testing services volume and revenue expansion.
CDNA
CareDx Completes Sale of Lab Products Business to Eurobio Scientific
CareDx closed the sale of its Lab Products business to Eurobio Scientific for $171.2 million. This divestiture sharpens the company's focus on its core U.S. precision medicine services and operating model.
CDNA
CareDx increases equity plan share reserve to 6.7 million shares
CareDx's board approved Amendment No. 2 to its 2024 Equity Incentive Plan, increasing the share reserve available for awards to 6.7 million shares, pending stockholder approval. This expansion allows the company greater flexibility in compensating employees and executives through equity grants.
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same CDNA feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/CDNA/newsSTART FREE